Amplia Therapeutics: Advancing Pancreatic Cancer Treatment

Proactive - Interviews for investors

Chris Burns, CEO of Amplia Therapeutics, shared promising updates with Steve Darling from Proactive regarding the company’s ongoing Phase 2a clinical trial focused on treating advanced pancreatic cancer. Burns announced that a fifth patient enrolled in the trial has achieved a confirmed partial response, indicating a 30% or greater reduction in the overall size of tumor lesions, which has been maintained over a two-month period with no new tumor lesions appearing. Additionally, Burns reported that six other patients in the trial have shown stable disease at both their two-month and four-month assessment time points. According to RECIST 1.1 criteria, stable disease (SD) is noted when tumor lesions have either reduced in size by less than 30% or have shown minimal to no growth. The Phase 2a ACCENT trial is exploring the efficacy of Amplia Therapeutics’ lead asset, narmafotinib, in treating advanced pancreatic cancer. The trial plans to enroll a total of 50 patients, with the first cohort consisting of 26 patients. Responses to the therapy are monitored every two months, and the recruitment of the second cohort of 24 patients will commence once a minimum of six patients have recorded a confirmed partial or complete response. #proactiveinvestors #ampliatherapeuticslimited #asx #atx #PancreaticCancer #CancerTreatment #ClinicalTrial #Biotech #HealthcareInnovation #Pharmaceuticals #Oncology #CancerResearch #MedicalBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews